In about three years, a new drug for depression could be ready for the market: psilocybin. So far, the magic mushroom active ingredient has been banned. Researchers, therapists and start-up founders are fighting for its medical recognition. But can the substance really deliver what it promises?
by Jochen Metzger
Something in Lars Wilde’s life breaks on his home sofa. He is in his early 30s and has already founded several companies. His current start-up sells things you use in the kitchen online: electric milk frothers, acacia cutting boards, stoneware egg cups. It’s the beginning of January when Lars Wilde is poring over his company’s annual balance sheet when his mobile phone vibrates. Message follows message and everyone says the same thing: Holger is dead.